End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

Abstract

Recent trials in glioma have revealed significant limitations in the end points used. This requires a critical and comprehensive review of how brain tumor trials are conducted, particularly of which end points are defined and how response and progression are defined.